Clinical Trial Update: Combining Ipilimumab, Degarelix, and Radical Prostatectomy in Men With Newly Diagnosed Metastatic Castration Sensitive Prostate Cancer or Ipilimumab and Degarelix in Men With Biochemically Recurrent Castration Sensitive Prostate Cancer After Radical Prostatectomy [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating the combination of ipilimumab, degarelix, and radical prostatectomy in men with newly diagnosed metastatic castration-sensitiv…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Biochemical Recurrence of Prostate Cancer After Radical Prostatectomy
• Castration-sensitive Prostate Cancer
• Prostate Cancer

Drugs mentioned

• degarelix (degarelix)
• ipilimumab (ipilimumab)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Metastatic Castration Sensitive Prostate Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING